Jane A. Little
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jane A. Little has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
- Umut Atakan Gurkan
Department of Mechanical and Aerospace Engineering Case Western Reserve University Cleveland Ohio USA
5 shared publications - Erdem Kucukal
Case Western Reserve University, Cleveland, OH
4 shared publications - Ran An
Department of Mechanical and Aerospace Engineering, Case Western Reserve University, Cleveland, OH, USA
3 shared publications - Yuncheng Man
Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA 02215, USA
3 shared publications Karamoja Monchamp
Case Western Reserve University, Cleveland, OH
2 shared publications- Lalitha Nayak
University Hospitals Cleveland Medical Center, Cleveland, OH
2 shared publications
Latest Publications
- 16 November 2022
- Published by Elsevier in Hematology/Oncology Clinics of North America
- Vol. 36  (6)
Sickle Cell Syndromes
- 16 November 2022
- Published by Elsevier in Hematology/Oncology Clinics of North America
- Vol. 36  (6)
Sickle Cell Syndromes
- 15 November 2022
- Published by Elsevier in Hematology/Oncology Clinics of North America
- Vol. 36  (6) , XIII-XIV
Sickle Cell Disease: New Approaches for an Old Disease
- 15 November 2022
- Published by Elsevier in Hematology/Oncology Clinics of North America
- Vol. 36  (6) , XIII-XIV
Sickle Cell Disease: New Approaches for an Old Disease
- Open Access
Sickle red blood cell derived extracellular vesicles activate endothelial cells and enhance sickle red cell adhesion mediated by von Willebrand factor
Endothelial activation and sickle red blood cell (RBC) adhesion are central to the pathogenesis of sickle cell disease (SCD). Quantitatively, RBC-derived extracellular vesicles, REVs, are more abundant from SS RBCs compared with healthy RBCs (AA RBCs). Sickle RBC-derived REVs (SS REVs) are known to promote endothelial cell (EC) activation through cell signaling and transcriptional regulation at longer terms. However, the SS REV-mediated short term non transcriptional response of EC is unclear. Here, we examined the impact of SS REVs on acute microvascular EC activation and RBC adhesion at 2 hours. Compared with AA REVs, SS REVs promoted human pulmonary microvascular endothelial cells (HPMEC) activation indicated by increased von Willebrand Factor (vWF) expression. Under microfluidic conditions, we found abnormal SS RBC adhesion to HPMECs exposed to SS REVs. This enhanced SS RBC adhesion was reduced by vWF cleaving protease ADAMTS13 to a level similar to HPMECs treated with AA REVs. Consistent with these observations, studies in SS mice with implanted dorsal skin-fold chambers found hemin-induced stasis was inhibited by ADAMTS13. The adhesion induced by SS REVs was variable, and was higher with SS RBCs from patients with increased markers of hemolysis (LDH and reticulocyte count) or a concomitant clinical diagnosis of deep vein thrombosis. Our results emphasize the critical contribution made by REVs to the pathophysiology of SCD by triggering acute microvascular EC activation and abnormal RBC adhesion. These findings may help to better understand acute pathophysiological mechanism of SCD and thereby the development of new treatment strategies using vWF as a potential target.
Open AccessSickle red blood cell derived extracellular vesicles activate endothelial cells and enhance sickle red cell adhesion mediated by von Willebrand factor
Endothelial activation and sickle red blood cell (RBC) adhesion are central to the pathogenesis of sickle cell disease (SCD). Quantitatively, RBC-derived extracellular vesicles, REVs, are more abundant from SS RBCs compared with healthy RBCs (AA RBCs). Sickle RBC-derived REVs (SS REVs) are known to promote endothelial cell (EC) activation through cell signaling and transcriptional regulation at longer terms. However, the SS REV-mediated short term non transcriptional response of EC is unclear. Here, we examined the impact of SS REVs on acute microvascular EC activation and RBC adhesion at 2 hours. Compared with AA REVs, SS REVs promoted human pulmonary microvascular endothelial cells (HPMEC) activation indicated by increased von Willebrand Factor (vWF) expression. Under microfluidic conditions, we found abnormal SS RBC adhesion to HPMECs exposed to SS REVs. This enhanced SS RBC adhesion was reduced by vWF cleaving protease ADAMTS13 to a level similar to HPMECs treated with AA REVs. Consistent with these observations, studies in SS mice with implanted dorsal skin-fold chambers found hemin-induced stasis was inhibited by ADAMTS13. The adhesion induced by SS REVs was variable, and was higher with SS RBCs from patients with increased markers of hemolysis (LDH and reticulocyte count) or a concomitant clinical diagnosis of deep vein thrombosis. Our results emphasize the critical contribution made by REVs to the pathophysiology of SCD by triggering acute microvascular EC activation and abnormal RBC adhesion. These findings may help to better understand acute pathophysiological mechanism of SCD and thereby the development of new treatment strategies using vWF as a potential target.
- Open Access
- 5 November 2021
- Published by American Society of Hematology in Blood
- Vol. 138  (Supplement) , 966
Hypoxia Impact on Red Blood Cell-Mediated Microvascular Occlusion and Adhesion in Sickle Cell Disease and Sickle Cell Trait
Introduction: Sickle cell disease (SCD) is a recessively inherited anemia caused by a single gene mutation leading to sickle hemoglobin production. Sickle cell trait (SCT) is the carrier state. Abnormal hemoglobin polymerization and resultant red blood cell (RBC) sickling, decreased deformability and increased adhesion, are well-known features of homozygous SCD. However, the overall pathophysiological impact of SCT on the RBC remains incompletely characterized. Here we use microfluidic techniques designed by us, the OcclusionChip and SCD Biochip (previously published), and commercially available ektacytometry to investigate hypoxia impact on RBC biophysical properties in SCT. Methods: Venous blood samples were collected in EDTA from subjects with homozygous HbSS, SCT (HbAS), and non-anemic controls (HbAA) under an IRB-approved protocol. OcclusionChip devices were fabricated using standard soft lithography protocols [1]. RBCs were isolated from whole blood, re-suspended in PBS at 20% hematocrit, and passed through the OcclusionChip device with a constant inlet pressure. Following a wash step, the OcclusionChip microchannel was imaged, and Occlusion Index (OI), a standardized generalizable parameter we developed, representing the overall microcapillary network occlusion, was quantified. SCD Biochip microchannels were fabricated by lamination and were functionalized with human laminin (LN-511) [2]. Undiluted whole blood was injected into the microchannel at 1 dyne/cm 2, a shear stress value typically observed in the post-capillary venules. Following a wash step, the SCD Biochip microchannel was imaged, and the number of adherent RBCs in a 32-mm 2 window was quantified. For hypoxia experiments, a hypoxic setup was fabricated for blood deoxygenation (pO 2 ~45 mmHg) [3, 4]. Ektacytometry measurements were performed according to the manufacturers' specifications (Lorrca Maxsis). Data are reported as mean ± standard deviation (SD). Results: We initially analyzed RBC-mediated microvascular occlusion under normoxia or hypoxia using the OcclusionChip (Figure 1A). Under normoxia, HbSS-containing RBCs had relatively greater OI values compared to HbAA- and HbAS-containing RBCs (Figure 1B, P = 0.057 for HbSS vs HbAA and P = 0.060 for HbSS vs HbAS). However, exposure to hypoxia led to significantly elevated OI values in the HbAS- and HbSS-containing RBCs (Figure 1B, 0.05 ± 0.02% vs 33.62 ± 18.31%, P = 0.015 for HbAS, and 0.27 ± 0.24% vs 49.37 ± 24.47%, P = 0.001 for HbSS, normoxia vs hypoxia). Negligible occlusion was observed in HbAA-containing RBCs (Figure 1B). We then analyzed RBC adhesion to LN under normoxia or hypoxia using the SCD Biochip (Figure 1C). Hypoxia led to greater number of adherent RBCs on LN in the HbSS-containing RBCs (Figure 1D, 141 ± 91 vs 497 ± 392, P = 0.089, normoxia vs hypoxia), but this effect was not present in HbAA- or HbAS-containing RBCs (Figure 1B, 2 ± 1 vs 3 ± 1, P > 0.05 for HbAA, and 10 ± 7 vs 12 ± 3, P > 0.05 for HbAS, normoxia vs hypoxia). Further, under normoxia, we found that the HbAS-containing RBCs had slightly greater number of adherent RBCs on LN compared to the HbAA-containing RBCs (Figure 1D, P = 0.057 for HbAA vs HbAS). As previously reported, HbSS-containing RBCs showed greatest adhesion to LN under normoxia compared to the HbAA- and HbAS-containing RBCs (Figure 1D, P = 0.027 for HbSS vs HbAA and P = 0.033 for HbSS vs HbAS)., Finally, we preformed Lorrca oxyscan and found that ektacytometry is less sensitive to RBC deformability change under hypoxia in SCT (Figure 1E). Conclusions: Findings in this study suggest that although RBCs from subjects with SCT are deformable under normoxia and are able to clear narrow capillaries similar to normal RBCs, hypoxia changes deformability, presumably due to hypoxic polymer formation, and could contribute to microvascular occlusion in SCT. The OcclusionChip is a single cell-based technology, and may be more sensitive to single RBC deformability. Future studies will prospectively focus on analyzing RBC adhesion on activated microvascular endothelial cells in physiologic flow to further interrogate the impact of hypoxia on pathophysiology in SCT. References: [1] Man et al., LabChip, 2020, 20, 2086-2099. [2] Kim et al., Microcirculation, 2017, 24, e12374. Figure 1 Figure 1. Disclosures: An: Hemex Health, Inc.: Patents & Royalties. Kucukal: BioChip Labs: Current Employment, Patents & Royalties. Nayak: BioChip Labs: Patents & Royalties. Little: Biochip Labs: Patents & Royalties; Hemex Health, Inc.: Patents & Royalties. Gurkan: Dx Now Inc.: Patents & Royalties; Hemex Health, Inc.: Current Employment, Patents & Royalties; Biochip Labs: Patents & Royalties; Xatek Inc.: Patents & Royalties.
- 5 November 2021
- Published by American Society of Hematology in Blood
- Vol. 138  (Supplement) , 966
Open AccessHypoxia Impact on Red Blood Cell-Mediated Microvascular Occlusion and Adhesion in Sickle Cell Disease and Sickle Cell Trait
Introduction: Sickle cell disease (SCD) is a recessively inherited anemia caused by a single gene mutation leading to sickle hemoglobin production. Sickle cell trait (SCT) is the carrier state. Abnormal hemoglobin polymerization and resultant red blood cell (RBC) sickling, decreased deformability and increased adhesion, are well-known features of homozygous SCD. However, the overall pathophysiological impact of SCT on the RBC remains incompletely characterized. Here we use microfluidic techniques designed by us, the OcclusionChip and SCD Biochip (previously published), and commercially available ektacytometry to investigate hypoxia impact on RBC biophysical properties in SCT. Methods: Venous blood samples were collected in EDTA from subjects with homozygous HbSS, SCT (HbAS), and non-anemic controls (HbAA) under an IRB-approved protocol. OcclusionChip devices were fabricated using standard soft lithography protocols [1]. RBCs were isolated from whole blood, re-suspended in PBS at 20% hematocrit, and passed through the OcclusionChip device with a constant inlet pressure. Following a wash step, the OcclusionChip microchannel was imaged, and Occlusion Index (OI), a standardized generalizable parameter we developed, representing the overall microcapillary network occlusion, was quantified. SCD Biochip microchannels were fabricated by lamination and were functionalized with human laminin (LN-511) [2]. Undiluted whole blood was injected into the microchannel at 1 dyne/cm 2, a shear stress value typically observed in the post-capillary venules. Following a wash step, the SCD Biochip microchannel was imaged, and the number of adherent RBCs in a 32-mm 2 window was quantified. For hypoxia experiments, a hypoxic setup was fabricated for blood deoxygenation (pO 2 ~45 mmHg) [3, 4]. Ektacytometry measurements were performed according to the manufacturers' specifications (Lorrca Maxsis). Data are reported as mean ± standard deviation (SD). Results: We initially analyzed RBC-mediated microvascular occlusion under normoxia or hypoxia using the OcclusionChip (Figure 1A). Under normoxia, HbSS-containing RBCs had relatively greater OI values compared to HbAA- and HbAS-containing RBCs (Figure 1B, P = 0.057 for HbSS vs HbAA and P = 0.060 for HbSS vs HbAS). However, exposure to hypoxia led to significantly elevated OI values in the HbAS- and HbSS-containing RBCs (Figure 1B, 0.05 ± 0.02% vs 33.62 ± 18.31%, P = 0.015 for HbAS, and 0.27 ± 0.24% vs 49.37 ± 24.47%, P = 0.001 for HbSS, normoxia vs hypoxia). Negligible occlusion was observed in HbAA-containing RBCs (Figure 1B). We then analyzed RBC adhesion to LN under normoxia or hypoxia using the SCD Biochip (Figure 1C). Hypoxia led to greater number of adherent RBCs on LN in the HbSS-containing RBCs (Figure 1D, 141 ± 91 vs 497 ± 392, P = 0.089, normoxia vs hypoxia), but this effect was not present in HbAA- or HbAS-containing RBCs (Figure 1B, 2 ± 1 vs 3 ± 1, P > 0.05 for HbAA, and 10 ± 7 vs 12 ± 3, P > 0.05 for HbAS, normoxia vs hypoxia). Further, under normoxia, we found that the HbAS-containing RBCs had slightly greater number of adherent RBCs on LN compared to the HbAA-containing RBCs (Figure 1D, P = 0.057 for HbAA vs HbAS). As previously reported, HbSS-containing RBCs showed greatest adhesion to LN under normoxia compared to the HbAA- and HbAS-containing RBCs (Figure 1D, P = 0.027 for HbSS vs HbAA and P = 0.033 for HbSS vs HbAS)., Finally, we preformed Lorrca oxyscan and found that ektacytometry is less sensitive to RBC deformability change under hypoxia in SCT (Figure 1E). Conclusions: Findings in this study suggest that although RBCs from subjects with SCT are deformable under normoxia and are able to clear narrow capillaries similar to normal RBCs, hypoxia changes deformability, presumably due to hypoxic polymer formation, and could contribute to microvascular occlusion in SCT. The OcclusionChip is a single cell-based technology, and may be more sensitive to single RBC deformability. Future studies will prospectively focus on analyzing RBC adhesion on activated microvascular endothelial cells in physiologic flow to further interrogate the impact of hypoxia on pathophysiology in SCT. References: [1] Man et al., LabChip, 2020, 20, 2086-2099. [2] Kim et al., Microcirculation, 2017, 24, e12374. Figure 1 Figure 1. Disclosures: An: Hemex Health, Inc.: Patents & Royalties. Kucukal: BioChip Labs: Current Employment, Patents & Royalties. Nayak: BioChip Labs: Patents & Royalties. Little: Biochip Labs: Patents & Royalties; Hemex Health, Inc.: Patents & Royalties. Gurkan: Dx Now Inc.: Patents & Royalties; Hemex Health, Inc.: Current Employment, Patents & Royalties; Biochip Labs: Patents & Royalties; Xatek Inc.: Patents & Royalties.
- 1 May 2021
- Published by Elsevier in The Lancet Haematology
- Vol. 8  (5) , e307-e309
Sevuparin trial for acute pain in sickle cell disease: the dog that did not bark
- 1 May 2021
- Published by Elsevier in The Lancet Haematology
- Vol. 8  (5) , e307-e309
Sevuparin trial for acute pain in sickle cell disease: the dog that did not bark
- Open Access
- 5 November 2020
- Published by American Society of Hematology in Blood
- Vol. 136  (Supplement) , 24-25
Thrombin-Induced Endothelial Cell Damage Is Mitigated By Human Anti-Thrombin III in a Microfluidic Device
Introduction Sickle cell disease (SCD) is a pleiotropic disease that results in a hypercoagulable state due to the depletion of natural anticoagulants and abnormal activation of the coagulation cascade. Vascular inflammation is a characteristic of SCD and can lead to endothelial cell activation and abnormally enhanced adhesion of hematopoietic cells. These adhesive events can lead to vaso-occlusive crises and are thus a target of pharmaceutical exploration. The complex pathophysiology of SCD suggests that there are many potential therapeutic targets, particularly during activation of the coagulation cascade. Presently, we describe the use of a microfluidic device to investigate the effectiveness of anti-thrombin III (AT-III) in mitigating thrombin-mediated effects on and red blood cell adhesion (RBC) to endothelial cells. Our microfluidic device, endothelium-on-a-chip (Fig. 1A), incorporates microchannels functionalized with endothelial cells (ECs), which allows for investigation of SCD pathophysiology under physiological shear stress. Here, we examine the extent to which thrombin causes cellular contraction in human umbilical vein endothelial cells (HUVECs) and the capacity of AT-III to mitigate this contraction. Similarly, we quantify the adhesion of sickle RBCs to thrombin-activated HUVECs and the adhesion to HUVECs pre-treated with AT-III. Methods Microchannels seeded with human umbilical vein endothelial cells (HUVECs) were cultured to confluency under flow for 48 - 72 hrs at 37 °C in a 5% CO2 atmosphere. Culture media containing 10% fetal bovine serum (FBS) was perfused through the microchannels at a shear stress of 1 dyne/cm2 which corresponds to a typical value seen in human post-capillary venules. Approximately 18 hours prior to the start of the experiment, perfused media was exchanged for ITS+1 media in order to condition cells to a low-serum environment and to avoid neutralization of thrombin by residual serum factors. At the start of each experiment, devices were disconnected from the dynamic flow culturing system and incubated with experimental reagents under static conditions. Endothelialized microchannels were treated with one of three conditions: Control channels were incubated with ITS+1 media for 5 hrs; Thrombin channels were incubated with ITS+1 media for 1 hr, followed by 5 IU/mL human alpha thrombin for 4 hrs; Anti-thrombin III channels were incubated with 7 IU/mL human anti-thrombin III (AT-III) for 1 hr, followed by 5 IU/mL human alpha thrombin for 4 hrs. AT-III was donated by Grifols USA (Los Angeles, California). Following each experiment, the endothelialized microchannels were fixed with 3.7% formalin. Microchannels were then imaged and confluency was measured using the FIJI plug-in PHANTAST with default settings. For adhesion experiments, whole blood samples were collected from 6 patients with homozygous SCD (HbSS). RBCs were isolated and suspended at 20% hematocrit in basal media, then perfused through treated, endothelialized microchannels. Microchannels were then imaged and adherent RBCs were quantified. Results The results of contraction and adhesion experiments are shown in Figures 1B&C, respectively. Control channels had an average confluency of 97.9% ± 1.7 (Fig. 1B&D), while thrombin-treated channels resulted in HUVEC contraction causing an average confluency of 63.7% ± 8.9 (Fig. 1B&E). Microchannels treated with AT-III prior to thrombin incubation had an average confluency of 92.5% ± 5.3 (Fig. 1B&F). Adhesion of sickled RBCs followed a similar trend: control channels had an average of 16.0 ± 22.7 RBCs per analyzed region (Fig. 1C&G), thrombin channels had an average of 222.8 ± 86.7 RBCs per analyzed region (Fig. 1C&H), and AT-III channels had an average of 19.6 ± 12.3 RBCs per analyzed region (Fig. 1C&I). Discussion We observed that thrombin treatment resulted in significant endothelial cell contraction. This thrombin induced cell contraction could be mitigated by pre-treating the microchannels with AT-III. Similarly, RBC adhesion significantly increased in thrombin-treated microchannels, and could be similarly mitigated by pre-treatment of the endothelium with AT-III. Taken together, our in vitro model suggests that AT-III may be worthy of investigation as a treatment for SCD associated thromboinflammation and vaso-occlusive crises. Disclosures: An: Hemex Health, Inc.: Patents & Royalties. Little:NHLBI: Research Funding; GBT: Membership on an entity's Board of Directors or advisory committees; GBT: Research Funding; Bluebird Bio: Research Funding; BioChip Labs: Patents & Royalties: SCD Biochip (patent, no royalties); Hemex Health, Inc.: Patents & Royalties: Microfluidic electropheresis (patent, no royalties). Key:Novo Nordisk: Other: Chair of Grants Committee; Takeda: Research Funding; Grifols: Research Funding; Uniqure: Consultancy. Gurkan:Hemex Health, Inc.: Consultancy, Current Employment, Patents & Royalties, Research Funding; BioChip Labs: Patents & Royalties; Dx Now Inc.: Patents & Royalties; Xatek Inc.: Patents & Royalties.
- 5 November 2020
- Published by American Society of Hematology in Blood
- Vol. 136  (Supplement) , 24-25
Open AccessThrombin-Induced Endothelial Cell Damage Is Mitigated By Human Anti-Thrombin III in a Microfluidic Device
Introduction Sickle cell disease (SCD) is a pleiotropic disease that results in a hypercoagulable state due to the depletion of natural anticoagulants and abnormal activation of the coagulation cascade. Vascular inflammation is a characteristic of SCD and can lead to endothelial cell activation and abnormally enhanced adhesion of hematopoietic cells. These adhesive events can lead to vaso-occlusive crises and are thus a target of pharmaceutical exploration. The complex pathophysiology of SCD suggests that there are many potential therapeutic targets, particularly during activation of the coagulation cascade. Presently, we describe the use of a microfluidic device to investigate the effectiveness of anti-thrombin III (AT-III) in mitigating thrombin-mediated effects on and red blood cell adhesion (RBC) to endothelial cells. Our microfluidic device, endothelium-on-a-chip (Fig. 1A), incorporates microchannels functionalized with endothelial cells (ECs), which allows for investigation of SCD pathophysiology under physiological shear stress. Here, we examine the extent to which thrombin causes cellular contraction in human umbilical vein endothelial cells (HUVECs) and the capacity of AT-III to mitigate this contraction. Similarly, we quantify the adhesion of sickle RBCs to thrombin-activated HUVECs and the adhesion to HUVECs pre-treated with AT-III. Methods Microchannels seeded with human umbilical vein endothelial cells (HUVECs) were cultured to confluency under flow for 48 - 72 hrs at 37 °C in a 5% CO2 atmosphere. Culture media containing 10% fetal bovine serum (FBS) was perfused through the microchannels at a shear stress of 1 dyne/cm2 which corresponds to a typical value seen in human post-capillary venules. Approximately 18 hours prior to the start of the experiment, perfused media was exchanged for ITS+1 media in order to condition cells to a low-serum environment and to avoid neutralization of thrombin by residual serum factors. At the start of each experiment, devices were disconnected from the dynamic flow culturing system and incubated with experimental reagents under static conditions. Endothelialized microchannels were treated with one of three conditions: Control channels were incubated with ITS+1 media for 5 hrs; Thrombin channels were incubated with ITS+1 media for 1 hr, followed by 5 IU/mL human alpha thrombin for 4 hrs; Anti-thrombin III channels were incubated with 7 IU/mL human anti-thrombin III (AT-III) for 1 hr, followed by 5 IU/mL human alpha thrombin for 4 hrs. AT-III was donated by Grifols USA (Los Angeles, California). Following each experiment, the endothelialized microchannels were fixed with 3.7% formalin. Microchannels were then imaged and confluency was measured using the FIJI plug-in PHANTAST with default settings. For adhesion experiments, whole blood samples were collected from 6 patients with homozygous SCD (HbSS). RBCs were isolated and suspended at 20% hematocrit in basal media, then perfused through treated, endothelialized microchannels. Microchannels were then imaged and adherent RBCs were quantified. Results The results of contraction and adhesion experiments are shown in Figures 1B&C, respectively. Control channels had an average confluency of 97.9% ± 1.7 (Fig. 1B&D), while thrombin-treated channels resulted in HUVEC contraction causing an average confluency of 63.7% ± 8.9 (Fig. 1B&E). Microchannels treated with AT-III prior to thrombin incubation had an average confluency of 92.5% ± 5.3 (Fig. 1B&F). Adhesion of sickled RBCs followed a similar trend: control channels had an average of 16.0 ± 22.7 RBCs per analyzed region (Fig. 1C&G), thrombin channels had an average of 222.8 ± 86.7 RBCs per analyzed region (Fig. 1C&H), and AT-III channels had an average of 19.6 ± 12.3 RBCs per analyzed region (Fig. 1C&I). Discussion We observed that thrombin treatment resulted in significant endothelial cell contraction. This thrombin induced cell contraction could be mitigated by pre-treating the microchannels with AT-III. Similarly, RBC adhesion significantly increased in thrombin-treated microchannels, and could be similarly mitigated by pre-treatment of the endothelium with AT-III. Taken together, our in vitro model suggests that AT-III may be worthy of investigation as a treatment for SCD associated thromboinflammation and vaso-occlusive crises. Disclosures: An: Hemex Health, Inc.: Patents & Royalties. Little:NHLBI: Research Funding; GBT: Membership on an entity's Board of Directors or advisory committees; GBT: Research Funding; Bluebird Bio: Research Funding; BioChip Labs: Patents & Royalties: SCD Biochip (patent, no royalties); Hemex Health, Inc.: Patents & Royalties: Microfluidic electropheresis (patent, no royalties). Key:Novo Nordisk: Other: Chair of Grants Committee; Takeda: Research Funding; Grifols: Research Funding; Uniqure: Consultancy. Gurkan:Hemex Health, Inc.: Consultancy, Current Employment, Patents & Royalties, Research Funding; BioChip Labs: Patents & Royalties; Dx Now Inc.: Patents & Royalties; Xatek Inc.: Patents & Royalties.
- Open Access
- 29 November 2018
- Published by American Society of Hematology in Blood
- Vol. 132  (Supplement) , 1404
Comparison of Pegfilgrastim and Filgrastim to Prevent Neutropenic Fever during Consolidation with High Dose Cytarabine for Acute Myeloid Leukemia
Background: Granulocyte colony stimulating factor (G-CSF) to prevent neutropenic fever is a well-accepted standard of care to minimize the risk of neutropenic fever during consolidation chemotherapy for acute myeloid leukemia (AML). Although prospective, randomized clinical trials of filgrastim versus depot pegfilgrastim demonstrated biologic equivalency, retrospective studies in patients with solid tumors suggest the use of pegfilgrastim results in reduced rates of admission for neutropenic fever. Patients undergoing AML consolidation may be at higher risk for admission, as with solid tumors. Biosimilars for filgrastim (filgrastim-sndz and tbo-filgrastim) and pegfilgrastim (pegfilgrastim-jmdb) are creating market forces that may make daily administered agents an attractive alternative to pegfilgrastim, and therefore additional observational studies to clarify of the safety of daily administered G-CSF vs depot injections. We hypothesize that the use filgrastim over pegfilgrastim may result in higher hospital admission rates in AML patients undergoing consolidation chemotherapy outside the setting of prospective trials. Methods: Patient charts from the year 2004 through early 2017 diagnosed with AML at the Seidman Cancer Center of University Hospitals Cleveland Medical Center (UHCMC) were reviewed as a retrospective cohort study. Patient were included who received at least one cycle of high dose cytarabine during 1st complete remission, and received filgrastim or pegfilgrastim were considered available for analysis. Individual cycles of chemotherapy were assessed for potential adverse outcomes with the use of different forms of GCSF. The primary outcome of interest is hospitalization during consolidation chemotherapy. The incidence of hospitalization was analyzed using longitudinal logistic regression with generalized estimating equations for statistical inference assuming exchangeable variance-covariance structure of multiple hospitalizations from the same patients. Results 436 patient charts were reviewed identifying 165 patients receiving at least one cycle of HiDAC chemotherapy. Of these, 156 patients received either filgrastim or pegfilgrastim, representing 256 cycles of high dose cytarabine chemotherapy supported with GCSF. Patients receiving filgrastims vs pegfilgrastim differed in the number of HiDAC cycles received (1.64 vs 1.97, p = 0.046), the distribution of favorable risk AML (11.9% vs 32.7%, p = 0.035). Groups did not differ based on age, sex, race, initial response to therapy, and proportion of secondary AML. After controlling the effects of age, sex, race and initial clinical response, treatment (filgrastim vs. pegfilgrastim) was significantly associated with hospitalization during consolidation therapy (p = 0.005). Specifically, the odds of having hospitalization for patients treated with Filgrastim is estimated to be 2.31 times the odds of having hospitalization for patients treated Pegfilgrastim with 95% CI (1.28, 4.17). Also, the estimated probability of having hospitalization for patients treated with filgrastim was 0.59 (95% CI: 0.43- 0.73) vs. 0.38 (95% CI: 0.27 - 0.51) for patients treated with pegfilgrastim. Conclusions: The use of filgrastim was found to be statistically significantly associated with and increased risk of hospitalization.
- 29 November 2018
- Published by American Society of Hematology in Blood
- Vol. 132  (Supplement) , 1404
Open AccessComparison of Pegfilgrastim and Filgrastim to Prevent Neutropenic Fever during Consolidation with High Dose Cytarabine for Acute Myeloid Leukemia
Background: Granulocyte colony stimulating factor (G-CSF) to prevent neutropenic fever is a well-accepted standard of care to minimize the risk of neutropenic fever during consolidation chemotherapy for acute myeloid leukemia (AML). Although prospective, randomized clinical trials of filgrastim versus depot pegfilgrastim demonstrated biologic equivalency, retrospective studies in patients with solid tumors suggest the use of pegfilgrastim results in reduced rates of admission for neutropenic fever. Patients undergoing AML consolidation may be at higher risk for admission, as with solid tumors. Biosimilars for filgrastim (filgrastim-sndz and tbo-filgrastim) and pegfilgrastim (pegfilgrastim-jmdb) are creating market forces that may make daily administered agents an attractive alternative to pegfilgrastim, and therefore additional observational studies to clarify of the safety of daily administered G-CSF vs depot injections. We hypothesize that the use filgrastim over pegfilgrastim may result in higher hospital admission rates in AML patients undergoing consolidation chemotherapy outside the setting of prospective trials. Methods: Patient charts from the year 2004 through early 2017 diagnosed with AML at the Seidman Cancer Center of University Hospitals Cleveland Medical Center (UHCMC) were reviewed as a retrospective cohort study. Patient were included who received at least one cycle of high dose cytarabine during 1st complete remission, and received filgrastim or pegfilgrastim were considered available for analysis. Individual cycles of chemotherapy were assessed for potential adverse outcomes with the use of different forms of GCSF. The primary outcome of interest is hospitalization during consolidation chemotherapy. The incidence of hospitalization was analyzed using longitudinal logistic regression with generalized estimating equations for statistical inference assuming exchangeable variance-covariance structure of multiple hospitalizations from the same patients. Results 436 patient charts were reviewed identifying 165 patients receiving at least one cycle of HiDAC chemotherapy. Of these, 156 patients received either filgrastim or pegfilgrastim, representing 256 cycles of high dose cytarabine chemotherapy supported with GCSF. Patients receiving filgrastims vs pegfilgrastim differed in the number of HiDAC cycles received (1.64 vs 1.97, p = 0.046), the distribution of favorable risk AML (11.9% vs 32.7%, p = 0.035). Groups did not differ based on age, sex, race, initial response to therapy, and proportion of secondary AML. After controlling the effects of age, sex, race and initial clinical response, treatment (filgrastim vs. pegfilgrastim) was significantly associated with hospitalization during consolidation therapy (p = 0.005). Specifically, the odds of having hospitalization for patients treated with Filgrastim is estimated to be 2.31 times the odds of having hospitalization for patients treated Pegfilgrastim with 95% CI (1.28, 4.17). Also, the estimated probability of having hospitalization for patients treated with filgrastim was 0.59 (95% CI: 0.43- 0.73) vs. 0.38 (95% CI: 0.27 - 0.51) for patients treated with pegfilgrastim. Conclusions: The use of filgrastim was found to be statistically significantly associated with and increased risk of hospitalization.
- Open Access
- 7 December 2017
- Published by American Society of Hematology in Blood
- Vol. 130  (Suppl_1) , 959
Adhesion of Sickle RBCs to Heme-Activated Endothelial Cells Correlates with Patient Clinical Phenotypes
Severe hemolysis and associated high levels of hemolytic biomarkers, including LDH and heme, are among major constituents of the pathophysiology of sickle cell disease (SCD). Elevated extracellular heme due to hemolysis overwhelms endogenous detoxification mechanisms and leads to oxidative stress, triggering systemic endothelium activation, vascular dysfunction, and end organ damage. To understand the role of red blood cells (RBC) in this process, we assessed sickle RBC adhesion to heme-activated endothelial cells utilizing an endothelialized microfluidic platform in a clinically diverse patient population. Human umbilical vein endothelial cells (HUVECs) were seeded into fibronectin (FN) functionalized microfluidic channels and incubated for 4 hours in a 37°C and 5% CO2 environment. Next, the confluent monolayers were loaded and incubated for 45 minutes with fresh culture medium or at one of two concentrations of heme solutions: (1) 20 μM that corresponds to physiological heme levels in SCD patients, and (2) 40 μM. SCD blood samples, collected from 8 patients (7 HbSS and 1 HbS/β0 thal; 3 males and 5 females), were centrifuged to remove the plasma and washed with PBS thrice prior to flow experiments. RBCs were re-suspended in culture medium at a hematocrit of 25%. A total volume of 15 µl RBC suspension was perfused into the microchannels followed by rinsing with fresh culture medium at 1 dyne/cm2, which corresponds to the typical shear stress value observed in post-capillary venules. The fully closed and hermetically sealed microfluidic system design ensured the stability of gas composition in the culture medium during the experiments. Endothelialized microchannels supported sickle RBC adhesion to non-treated, 20 µM heme-activated, and 40 µM heme-activated HUVECs (Fig. 1A, B, C). Adhesion results suggested that activation of HUVECs by heme mediated RBC adhesion in a concentration-dependent manner, with a significant difference observed at 40 µM (Fig. 1D, paired t-test, p200 adherent RBCs) had elevations in serum LDH levels and in absolute reticulocyte counts. Moreover, patients with a recent transfusion had higher RBC adhesion to 40 µM heme-activated HUVECs compared to patients with no transfusion in the last 3 months (Fig. 1H, pin vivo may also be those RBCs most likely to adhere to heme-activated endothelium. Acknowledgments: This work was supported by grants #2013126 and #2015191 from the Doris Duke Charitable Foundation, National Heart Lung and Blood Institute R01HL133574, and National Science Foundation CAREER Award 1552782. Figure 1: Sickle RBC adhesion to heme-activated HUVECs and clinical associations. Sickle RBCs adherent to immobilized HUVECs in (A) non-activated, (B) 20 µM heme-activated, and (C) 40 µM heme-activated microchannels. The microscope images illustrate a small portion of the full microchannel surface. (D) RBC adhesion to HUVECs increased depending on the heme concentration, with a significant difference at the 40 µM level (paired t test, p(E) as well as absolute reticulocyte counts (F), and lower total hemoglobin (G) showed significantly greater RBC adhesion to 20 µM heme-activated HUVECs (ANOVA). (H) Furthermore, patients with a recent transfusion history displayed elevated RBC adhesion to 40 µM heme-activated HUVECs compared to non-transfused patients (ANOVA). The dashed rectangles indicate the normal clinical values for healthy individuals, while all patients had total hemoglobin levels lower than normal. Scale bars represent 30 µm.
- 7 December 2017
- Published by American Society of Hematology in Blood
- Vol. 130  (Suppl_1) , 959
Open AccessAdhesion of Sickle RBCs to Heme-Activated Endothelial Cells Correlates with Patient Clinical Phenotypes
Severe hemolysis and associated high levels of hemolytic biomarkers, including LDH and heme, are among major constituents of the pathophysiology of sickle cell disease (SCD). Elevated extracellular heme due to hemolysis overwhelms endogenous detoxification mechanisms and leads to oxidative stress, triggering systemic endothelium activation, vascular dysfunction, and end organ damage. To understand the role of red blood cells (RBC) in this process, we assessed sickle RBC adhesion to heme-activated endothelial cells utilizing an endothelialized microfluidic platform in a clinically diverse patient population. Human umbilical vein endothelial cells (HUVECs) were seeded into fibronectin (FN) functionalized microfluidic channels and incubated for 4 hours in a 37°C and 5% CO2 environment. Next, the confluent monolayers were loaded and incubated for 45 minutes with fresh culture medium or at one of two concentrations of heme solutions: (1) 20 μM that corresponds to physiological heme levels in SCD patients, and (2) 40 μM. SCD blood samples, collected from 8 patients (7 HbSS and 1 HbS/β0 thal; 3 males and 5 females), were centrifuged to remove the plasma and washed with PBS thrice prior to flow experiments. RBCs were re-suspended in culture medium at a hematocrit of 25%. A total volume of 15 µl RBC suspension was perfused into the microchannels followed by rinsing with fresh culture medium at 1 dyne/cm2, which corresponds to the typical shear stress value observed in post-capillary venules. The fully closed and hermetically sealed microfluidic system design ensured the stability of gas composition in the culture medium during the experiments. Endothelialized microchannels supported sickle RBC adhesion to non-treated, 20 µM heme-activated, and 40 µM heme-activated HUVECs (Fig. 1A, B, C). Adhesion results suggested that activation of HUVECs by heme mediated RBC adhesion in a concentration-dependent manner, with a significant difference observed at 40 µM (Fig. 1D, paired t-test, p200 adherent RBCs) had elevations in serum LDH levels and in absolute reticulocyte counts. Moreover, patients with a recent transfusion had higher RBC adhesion to 40 µM heme-activated HUVECs compared to patients with no transfusion in the last 3 months (Fig. 1H, pin vivo may also be those RBCs most likely to adhere to heme-activated endothelium. Acknowledgments: This work was supported by grants #2013126 and #2015191 from the Doris Duke Charitable Foundation, National Heart Lung and Blood Institute R01HL133574, and National Science Foundation CAREER Award 1552782. Figure 1: Sickle RBC adhesion to heme-activated HUVECs and clinical associations. Sickle RBCs adherent to immobilized HUVECs in (A) non-activated, (B) 20 µM heme-activated, and (C) 40 µM heme-activated microchannels. The microscope images illustrate a small portion of the full microchannel surface. (D) RBC adhesion to HUVECs increased depending on the heme concentration, with a significant difference at the 40 µM level (paired t test, p(E) as well as absolute reticulocyte counts (F), and lower total hemoglobin (G) showed significantly greater RBC adhesion to 20 µM heme-activated HUVECs (ANOVA). (H) Furthermore, patients with a recent transfusion history displayed elevated RBC adhesion to 40 µM heme-activated HUVECs compared to non-transfused patients (ANOVA). The dashed rectangles indicate the normal clinical values for healthy individuals, while all patients had total hemoglobin levels lower than normal. Scale bars represent 30 µm.
- Open Access
- 2 December 2016
- Published by American Society of Hematology in Blood
- Vol. 128  (22) , 3643
Hypoxia Responsiveness in RBCs from Patients with Sickle Cell Disease Associates with a More Severe Clinical Phenotype
Abnormal cellular interactions and adhesion of blood cells to endothelium under hypoxic conditions are pathophysiologically central to Sickle Cell Disease (SCD). Analysis of the germane cellular interactions in physiologically relevant flow and oxygen tension conditions is technically challenging. We developed a low-cost, single-use micro-gas exchanger, integrated with a microfluidic device, with which to evaluate the effects of hypoxia. This system can simulate a range of physiological conditions, under which to analyze red blood cell (RBC) adhesion to endothelial or sub-endothelial components (here fibronectin, FN, or laminin, LN). 15 µL of surplus whole blood was injected on to FN- or LN-functionalized microchannels, after passing through a micro-gas exchanger composed of a gas permeable inner tubing inside a gas impermeable outer tubing (Fig. 1A). Blood flowed, and was deoxygenated, within the inner gas permeable tubing, while a controlled gas mixture (5% CO2 and 95% N2) flowed in the space between inner and outer tubing. Blood samples were flown into microchannels at physiological flow conditions (1 dyne/cm2), and at normoxic (98% SpO2) or hypoxic oxygen saturations (83% SpO2). Serial quantitative evaluation of RBC adhesion, using standardized protocols, were on >35 subjects (13 males and 22 females) with homozygous HbSS patients on whom we have correlative clinical data (institutional review board approved study). Significant heterogeneity in the RBC adherence response to hypoxia was seen among SCD patients. RBCs from a hypoxia responsive (HR) population showed a significantly greater increase in adhesion compared to RBCs from a hypoxia non-responsive (non-HR) population, for both FN and LN (Fig. 1B, p=0.0001, one-way ANOVA). RBCs from the non-HR patient population had higher HbF values than did RBCs from the HR patient population (p=0.0079, one-way ANOVA). All HR RBCs had <7% HbF. Furthermore, patients with HR RBCs had significantly higher serum ferritin (p=0.0024, one-way ANOVA) and LDH levels (p=0.0128, one-way ANOVA), and higher reticulocyte counts (Fig. 1C, p<0.0001, one-way ANOVA) than did patients with non-HR RBCs. We also observed that 7 out of 8 subjects in HR subpopulation were transfused, whereas only 2 out of 15 subjects in the non-HR subpopulation were transfused (Fig. 1C). Moreover, the age distribution of HR patients was significantly younger (<35 years) than non-HR patients (Fig. 1D, p<0.05, Chi-Square). We suspect that the HR RBC phenotype associates with greater clinical disease activity, and more intensive therapeutic interventions, i.e., transfusions, overall. Here, we reported adhesion of RBCs to endothelium associated proteins, FN and LN, under normoxic and hypoxic conditions, in a closed microscale environment under physiologically relevant flow conditions. The approach and technique presented here enabled us to control the oxygen tension of the blood in flow and to quantify the adhesion response of RBCs with SCD in a cost-efficient and patient-specific manner, demonstrating the effectiveness of our system. We identified a unique patient population whose RBCs, designated as 'hypoxia-responsive' (HR), showed enhanced adhesion, to LN and FN, in response to hypoxia in vitro. Clinical correlates suggest a more severe clinical in vivo SCD phenotype in this subgroup. Acknowledgments: This work was supported by Grant # 2013126 from the Doris Duke Charitable Foundation and National Heart Lung and Blood Institute R01HL133574. Authors acknowledge Grace Gongaware for scientific illustrations, and contributions of patients and health care providers at University Hospitals.
- 2 December 2016
- Published by American Society of Hematology in Blood
- Vol. 128  (22) , 3643
Open AccessHypoxia Responsiveness in RBCs from Patients with Sickle Cell Disease Associates with a More Severe Clinical Phenotype
Abnormal cellular interactions and adhesion of blood cells to endothelium under hypoxic conditions are pathophysiologically central to Sickle Cell Disease (SCD). Analysis of the germane cellular interactions in physiologically relevant flow and oxygen tension conditions is technically challenging. We developed a low-cost, single-use micro-gas exchanger, integrated with a microfluidic device, with which to evaluate the effects of hypoxia. This system can simulate a range of physiological conditions, under which to analyze red blood cell (RBC) adhesion to endothelial or sub-endothelial components (here fibronectin, FN, or laminin, LN). 15 µL of surplus whole blood was injected on to FN- or LN-functionalized microchannels, after passing through a micro-gas exchanger composed of a gas permeable inner tubing inside a gas impermeable outer tubing (Fig. 1A). Blood flowed, and was deoxygenated, within the inner gas permeable tubing, while a controlled gas mixture (5% CO2 and 95% N2) flowed in the space between inner and outer tubing. Blood samples were flown into microchannels at physiological flow conditions (1 dyne/cm2), and at normoxic (98% SpO2) or hypoxic oxygen saturations (83% SpO2). Serial quantitative evaluation of RBC adhesion, using standardized protocols, were on >35 subjects (13 males and 22 females) with homozygous HbSS patients on whom we have correlative clinical data (institutional review board approved study). Significant heterogeneity in the RBC adherence response to hypoxia was seen among SCD patients. RBCs from a hypoxia responsive (HR) population showed a significantly greater increase in adhesion compared to RBCs from a hypoxia non-responsive (non-HR) population, for both FN and LN (Fig. 1B, p=0.0001, one-way ANOVA). RBCs from the non-HR patient population had higher HbF values than did RBCs from the HR patient population (p=0.0079, one-way ANOVA). All HR RBCs had <7% HbF. Furthermore, patients with HR RBCs had significantly higher serum ferritin (p=0.0024, one-way ANOVA) and LDH levels (p=0.0128, one-way ANOVA), and higher reticulocyte counts (Fig. 1C, p<0.0001, one-way ANOVA) than did patients with non-HR RBCs. We also observed that 7 out of 8 subjects in HR subpopulation were transfused, whereas only 2 out of 15 subjects in the non-HR subpopulation were transfused (Fig. 1C). Moreover, the age distribution of HR patients was significantly younger (<35 years) than non-HR patients (Fig. 1D, p<0.05, Chi-Square). We suspect that the HR RBC phenotype associates with greater clinical disease activity, and more intensive therapeutic interventions, i.e., transfusions, overall. Here, we reported adhesion of RBCs to endothelium associated proteins, FN and LN, under normoxic and hypoxic conditions, in a closed microscale environment under physiologically relevant flow conditions. The approach and technique presented here enabled us to control the oxygen tension of the blood in flow and to quantify the adhesion response of RBCs with SCD in a cost-efficient and patient-specific manner, demonstrating the effectiveness of our system. We identified a unique patient population whose RBCs, designated as 'hypoxia-responsive' (HR), showed enhanced adhesion, to LN and FN, in response to hypoxia in vitro. Clinical correlates suggest a more severe clinical in vivo SCD phenotype in this subgroup. Acknowledgments: This work was supported by Grant # 2013126 from the Doris Duke Charitable Foundation and National Heart Lung and Blood Institute R01HL133574. Authors acknowledge Grace Gongaware for scientific illustrations, and contributions of patients and health care providers at University Hospitals.
- 1 August 2015
- Published by Elsevier in Blood Cells, Molecules, and Diseases
- Vol. 55  (2) , 161-167
Intermediaries of branched chain amino acid metabolism induce fetal hemoglobin, and repress SOX6 and BCL11A, in definitive erythroid cells
- 1 August 2015
- Published by Elsevier in Blood Cells, Molecules, and Diseases
- Vol. 55  (2) , 161-167
Intermediaries of branched chain amino acid metabolism induce fetal hemoglobin, and repress SOX6 and BCL11A, in definitive erythroid cells